Title:
TREATMENT OF ENDOCRINE RESISTANT BREAST CANCER
Document Type and Number:
WIPO Patent Application WO/2011/128434
Kind Code:
A3
Abstract:
The invention relates to pyrimidylaminobenzamides of formula (I) and other suitable PDGF-R inhibitors, alone or in combination with at least one aromatase inhibitor for the treatment of endocrine resistant breast cancer and to a method of treating warm-blooded animals including humans suffering from endocrine resistant breast cancer by administering to a said animal in need of such treatment an effective dose of a pyrimidylaminobenzamide of formula I alone or in combination with an aromatase inhibitor.
More Like This:
| WO/2024/049926 | DOSAGE REGIMENS OF ESTROGEN RECEPTOR DEGRADERS |
| WO/2007/078813 | 2-AMINO-5-PIPERIDINYLIMIDAZOLONE COMPOUNDS AND USE THEREOF FOR β-SECRETASE MODULATION |
| WO/2017/116937 | HAIR GROWTH COMPOSITION AND METHOD |
Inventors:
DOWSETT MITCH (GB)
GHAZOUI ZARA (GB)
MARTIN LESLEY-ANN (GB)
MUNDHENKE CHRISTOPH (DE)
WEIGEL MARION (GB)
GHAZOUI ZARA (GB)
MARTIN LESLEY-ANN (GB)
MUNDHENKE CHRISTOPH (DE)
WEIGEL MARION (GB)
Application Number:
PCT/EP2011/056003
Publication Date:
December 22, 2011
Filing Date:
April 15, 2011
Export Citation:
Assignee:
NOVARTIS AG (CH)
CANCER RES INST ROYAL (GB)
UNIVERSITAETSKLINIKUM SCHLESWIG HOLSTEIN (DE)
DOWSETT MITCH (GB)
GHAZOUI ZARA (GB)
MARTIN LESLEY-ANN (GB)
MUNDHENKE CHRISTOPH (DE)
WEIGEL MARION (GB)
CANCER RES INST ROYAL (GB)
UNIVERSITAETSKLINIKUM SCHLESWIG HOLSTEIN (DE)
DOWSETT MITCH (GB)
GHAZOUI ZARA (GB)
MARTIN LESLEY-ANN (GB)
MUNDHENKE CHRISTOPH (DE)
WEIGEL MARION (GB)
International Classes:
A61K31/506; A61K31/404; A61K31/4196; A61K31/4439; A61K31/445; A61K31/5685; A61K45/06; A61P35/00
Domestic Patent References:
| WO2007115289A2 | 2007-10-11 | |||
| WO2004005281A1 | 2004-01-15 |
Other References:
CHOW ET AL: "Evaluation of neoadjuvant inhibition of aromatase activity and signal transduction in breast cancer", CANCER LETTERS, NEW YORK, NY, US, vol. 262, no. 2, 14 January 2008 (2008-01-14), pages 232 - 238, XP022552580, ISSN: 0304-3835
B. ARUN, J. L. MURRAY, R. WALTERS, A. BREWSTER, E. RIVERA, V. VALERO, R. BAST, R. L. THERIAULT, M. GREEN, M. GREEN,: "The combination of letrozole and imatinib mesylate for metastatic breast cancer", PROGRAM/PROCEEDINGS - AMERICAN SOCIETY OF CLINICAL ONCOLOGY.ASCO, THE SOCIETY, US, 1 January 2009 (2009-01-01), pages 214, XP009138741
BRAMA MARINA ET AL: "Osteoblast-conditioned medium promotes proliferation and sensitizes breast cancer cells to imatinib treatment", ENDOCRINE-RELATED CANCER, vol. 14, no. 1, March 2007 (2007-03-01), pages 61 - 72, XP002600758, ISSN: 1351-0088
AHLGREN M THIRLWELL R O'REGAN C MORMONT L LEVESQUE R GASPO M WOLOJ A BELLO B MARTELL B LEYLAND-JONES P ET AL: "Sunitinib plus exemestane for the first-line treatment of hormone receptor-positive metastatic breast cancer: Results of an open-label study", PROGRAM/PROCEEDINGS - AMERICAN SOCIETY OF CLINICAL ONCOLOGY.ASCO, THE SOCIETY, US, 1 January 2009 (2009-01-01), XP009138666, ISSN: 1081-0641, [retrieved on 20100913]
COXON ANGELA ET AL: "Broad antitumor activity in breast cancer xenografts by motesanib, a highly selective, oral inhibitor of vascular endothelial growth factor, platelet-derived growth factor, and Kit receptors.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH 1 JAN 2009 LNKD- PUBMED:19118038, vol. 15, no. 1, 1 January 2009 (2009-01-01), pages 110 - 118, XP002600759, ISSN: 1078-0432
WEIGEL M T ET AL: "Combination of imatinib and vinorelbine enhances cell growth inhibition in breast cancer cells via PDGFR beta signalling", CANCER LETTERS, NEW YORK, NY, US LNKD- DOI:10.1016/J.CANLET.2008.07.040, vol. 273, no. 1, 8 January 2009 (2009-01-08), pages 70 - 79, XP025685877, ISSN: 0304-3835, [retrieved on 20080921]
BRUEGGEMEIER R W ET AL: "AROMATASE INHIBITORS IN THE TREATMENT OF BREAST CANCER", ENDOCRINE REVIEWS, BALTIMORE, MD, US, vol. 26, no. 3, 1 January 2005 (2005-01-01), pages 331 - 345, XP009059540
CHU DAVID ET AL: "Novel therapies in breast cancer: what is new from ASCO 2008", JOURNAL OF HEMATOLOGY & ONCOLOGY, BIOMED CENTRAL LTD, LONDON UK, vol. 1, no. 1, 1 October 2008 (2008-10-01), pages 16, XP021045985, ISSN: 1756-8722, DOI: 10.1186/1756-8722-1-16
See also references of EP 2558098A2
B. ARUN, J. L. MURRAY, R. WALTERS, A. BREWSTER, E. RIVERA, V. VALERO, R. BAST, R. L. THERIAULT, M. GREEN, M. GREEN,: "The combination of letrozole and imatinib mesylate for metastatic breast cancer", PROGRAM/PROCEEDINGS - AMERICAN SOCIETY OF CLINICAL ONCOLOGY.ASCO, THE SOCIETY, US, 1 January 2009 (2009-01-01), pages 214, XP009138741
BRAMA MARINA ET AL: "Osteoblast-conditioned medium promotes proliferation and sensitizes breast cancer cells to imatinib treatment", ENDOCRINE-RELATED CANCER, vol. 14, no. 1, March 2007 (2007-03-01), pages 61 - 72, XP002600758, ISSN: 1351-0088
AHLGREN M THIRLWELL R O'REGAN C MORMONT L LEVESQUE R GASPO M WOLOJ A BELLO B MARTELL B LEYLAND-JONES P ET AL: "Sunitinib plus exemestane for the first-line treatment of hormone receptor-positive metastatic breast cancer: Results of an open-label study", PROGRAM/PROCEEDINGS - AMERICAN SOCIETY OF CLINICAL ONCOLOGY.ASCO, THE SOCIETY, US, 1 January 2009 (2009-01-01), XP009138666, ISSN: 1081-0641, [retrieved on 20100913]
COXON ANGELA ET AL: "Broad antitumor activity in breast cancer xenografts by motesanib, a highly selective, oral inhibitor of vascular endothelial growth factor, platelet-derived growth factor, and Kit receptors.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH 1 JAN 2009 LNKD- PUBMED:19118038, vol. 15, no. 1, 1 January 2009 (2009-01-01), pages 110 - 118, XP002600759, ISSN: 1078-0432
WEIGEL M T ET AL: "Combination of imatinib and vinorelbine enhances cell growth inhibition in breast cancer cells via PDGFR beta signalling", CANCER LETTERS, NEW YORK, NY, US LNKD- DOI:10.1016/J.CANLET.2008.07.040, vol. 273, no. 1, 8 January 2009 (2009-01-08), pages 70 - 79, XP025685877, ISSN: 0304-3835, [retrieved on 20080921]
BRUEGGEMEIER R W ET AL: "AROMATASE INHIBITORS IN THE TREATMENT OF BREAST CANCER", ENDOCRINE REVIEWS, BALTIMORE, MD, US, vol. 26, no. 3, 1 January 2005 (2005-01-01), pages 331 - 345, XP009059540
CHU DAVID ET AL: "Novel therapies in breast cancer: what is new from ASCO 2008", JOURNAL OF HEMATOLOGY & ONCOLOGY, BIOMED CENTRAL LTD, LONDON UK, vol. 1, no. 1, 1 October 2008 (2008-10-01), pages 16, XP021045985, ISSN: 1756-8722, DOI: 10.1186/1756-8722-1-16
See also references of EP 2558098A2
Attorney, Agent or Firm:
ROTH, Peter R. (Patent Department, Basel, CH)
Download PDF:
Previous Patent: EXTERNALLY MIXING MULTI-COMPONENT NOZZLE
Next Patent: MIXING DEVICE HAVING A WEAR-RESISTANT LINING
Next Patent: MIXING DEVICE HAVING A WEAR-RESISTANT LINING